Lilly Sues Teva To Block Generic Symbyax
Teva is seeking U.S. Food and Drug Administration (FDA) approval to sell a low-cost version of bipolar depression treatment Symbyax, which combines ingredients from Lilly's Zyprexa schizophrenia medicine and Prozac antidepressant.
The FDA lists the filing of an Abbreviated New Drug Application (ANDA) for generic Symbyax on January 10, 2005, according to the agency’s website.
In its complaint, filed...
To view the full article, register now.